At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Vibegrondrug
Likely dose
Vibegron 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two-Part, Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Hepatic Insufficiency
In Brief
A Phase 1 clinical trial evaluating Vibegron for Overactive Bladder. Completed, enrolled 16 participants.
Detailed Summary
This study will investigate the pharmacokinetics of a single oral dose of vibegron (MK-4618) administered to participants with moderate hepatic insufficiency and healthy participants matched for age, gender, and body mass index (BMI). Participants may be enrolled with mild hepatic insufficiency.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartJan 2013
Primary CompletionJun 2013
TodayJul 2026
First PostedNov 29, 2012
Enrollment StartJan 15, 2013
Primary CompletionJun 14, 2013
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 13.6 years ago
Interventions
Vibegrondrug
50 mg tablet, oral